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INTRODUCTION
The amino-acid tyrosine (TYR) is thought
to modulate cognitive functions that are
driven by dopamine (DA), as consump-
tion of TYR enhances DA levels in the
brain (Gibson and Wurtman, 1977; Cuche
et al., 1985). It could therefore reverse
decreases in DA level that are detri-
mental for cognitive performance (Muly
et al., 1998; Goldman-Rakic et al., 2000;
Nieoullon, 2002). So far, TYR has been
considered not so much as an enhancer of
healthy cognitive functioning but rather as
a means to reduce the negative side-effects
of dopamine-related pathologies, such as
Parkinson’s disease (Growdon et al., 1982;
Lemoine et al., 1989), phenylketonuria
(van Spronsen et al., 1996), depression
(Gelenberg and Gibson, 1984), and atten-
tion deficit hyperactivity disorder (Wood
et al., 1985). However, the outcomes
were mixed: some patients reported sig-
nificant improvements, while other did
not. In clinical samples some variation in
response may be explained by impaired
processes such as DA synthesis, which
would lessen or even completely prevent
an effect of TYR. But even healthy sam-
ples differ in response to TYR supple-
mentation, which suggests that clinically
impaired DA function is not the only
source of variation.
The focus of the present opinion arti-
cle is not on clinical populations but
on TYR effects on cognitive control in
healthy humans. In healthy individuals,
TYR has often been used to reduce the
negative effects of conditions that deplete
the brain’s dopaminergic resources, such
as extreme stress. The supply of TYR was
found to reduce stress-induced impair-
ments of working memory and attentional
tasks, but more so in individuals who
were particularly sensitive to the stres-
sors (Deijen and Orlebeke, 1994; Shurtleff
et al., 1994; Mahoney et al., 2007).
Even without exposure to stress, admin-
istration of TYR has been shown to
have an acute beneficial effect on task-
performance thought to be related to DA,
e.g., simultaneously performing multiple
tasks (Thomas et al., 1999), the updat-
ing and monitoring of working memory
(Colzato et al., 2013a), and inhibitory
control (Colzato et al., 2014a). Taken
together, in healthy humans TYR seems
to work against what has been coined
“ego-depletion”—the exhaustion of lim-
ited cognitive control (CC) resources
(Baumeister et al., 1998). Demanding tasks
may deplete the available control resources
more, especially in individuals having
fewer resources and/or those that suffer
more from the situational demands, and
TYR may be able to replete the miss-
ing resources to some degree. This pos-
sibility should not be surprising given
that CC relies on DA (Cools, 2006). The
hypotheses that DA is one of the depleted
resources and TYR reverses its depletion
are consistent with the idea that there
is an optimal level of DA at which cog-
nitive performance peaks while it suf-
fers at lower levels (Muly et al., 1998;
Goldman-Rakic et al., 2000; Nieoullon,
2002). Given that TYR raises the DA level,
we argue that TYR can enhance cogni-
tive performance in healthy individuals
whenever one has a lower than optimal DA
level.
Besides individual differences in the
response to task-induced depletion, DA
level also seems to vary between healthy
individuals in a more stable and enduring
fashion (Cools, 2006; Cools et al., 2008,
2009). This suggests that individuals dif-
fer in how far away they are from their
optimum, i.e., some individuals have a lot
of room for improvement, while others
may already have an optimal, or even a
higher-than-optimal DA level. We expect
that individuals with an optimal base-
line have little left of the enzyme called
tyrosine-hydroxylase, which converts TYR
into DA (Daubner et al., 2011). This means
that they have little risk of overdosing
from TYR supplementation, instead they
should experience hardly any change in
performance.
Given that individuals can vary in their
response to TYR supplementation, it is
necessary that future studies on TYR take
into account individual differences, so to
ensure that samples are comparable and
results are generalizable. To this end we
discuss a number of DA-related measures
and factors that could predict or modu-
late the effect of TYR supplementation.
This is by no means an exhaustive list;
the aim of this opinion article is rather
to point out and highlight some accessible
predictors of DA function that may help
to improve designing future TYR studies
and making the analyses of their outcomes
more informative. To this date, the indi-
vidual differences discussed below have
not yet been investigated in combination
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with TYR. However, based on literature
that details their relation to DA function
we argue that these individual differences
will prove fruitful for future research.
INDICATORS AND MODULATORS OF
DA FUNCTION
At present, DA can only be measured (rel-
atively) directly using positron emission
tomography (PET), which is rather expen-
sive and invasive as it involves injecting
a radioactive substance into the blood-
stream (Volkow et al., 2009). Noninvasive
and cheap alternatives to estimate DA
function exist, and some can be found in
our eyes. The amacrine and interplexiform
cells of the retina contain a high concen-
tration of DA (Bodis-Wollner and Tzelepi,
1998; Witkovsky, 2004), and disorders
associated with DA dysfunction have been
related to abnormal color discrimination
(Pieri et al., 2000; Tannock et al., 2006;
Hulka et al., 2013). It has been proposed
that deficits in color vision, particularly
blue-yellow impairment, indicate a cen-
tral hypodopaminergic state (Roy et al.,
2003). This proposition is consistent with
the recent finding that color discrimina-
tion predicts cognitive control, with better
discrimination being associated with more
efficient conflict-resolution in an audi-
tory Simon task (Colzato et al., 2014b).
Given the relation between color vision
and DA level, we argue that color vision
can predict the effect of TYR supple-
mentation. Particularly individuals with
impaired color vision could benefit from
TYR, as they are likely to have less DA than
non-impaired peers.
Another interesting aspect of our eyes
is the spontaneous eye blink rate (EBR),
which has been found to reliably indi-
cate the striatal DA level (Karson, 1983).
Specifically, a higher EBR is associated
with more striatal DA. As expected, dis-
orders related to abnormal DA function
show atypical EBRs: Parkinson’s disease
is associated with decreased DA levels,
and correspondingly with decreased EBRs
(Deuschel and Goddemeier, 1998), while
schizophrenia is associated with increased
DA levels and increased EBRs (Freed,
1980). Also, EBR has been successfully
used to predict individual differences in
cognitive performance (e.g., Dreisbach
et al., 2005; Colzato et al., 2007b, 2008a,b,
2009). Given the relation between DA
and EBR, it follows that EBR can predict
the benefit of TYR supplementation. We
suggest that individuals with a low EBR,
indicative of a low DA level, stand to bene-
fit most from TYR, as it will bring their DA
level closer to the optimum that is asso-
ciated with peaking performance (Muly
et al., 1998; Goldman-Rakic et al., 2000).
Of further interest, striatal DA is thought
to be particularly involved in cognitive
flexibility (Cools, 2006)—the ability to
update and switch between mental repre-
sentations (Miyake et al., 2000). Therefore,
EBR might predict improvement in per-
formance especially on tasks that require a
flexible mind.
Moving on to gene polymorphisms, the
Val158Met-polymorphism in the catechol-
O-methyltransferase (COMT) gene could
also predict the effect of TYR supple-
mentation, as this gene is involved in
DA degradation in the prefrontal cor-
tex. Specifically, the Met allele is associ-
ated with slower degradation of DA and
high levels of prefrontal DA as the result,
whereas the Val allele is associated with
faster DA degradation and less prefrontal
DA (Chen et al., 2004). As expected, sev-
eral studies have shown Val-carriers to be
less adept at cognitive tasks than Met-
carriers (Egan et al., 2001; Mattay et al.,
2003; Goldberg and Weinberger, 2004),
which suggests that Val-carriers have lesser
DA. This again implies that Val-carriers
stand to benefit from TYR supplementa-
tion. Of further interest is the fact that
prefrontal DA is tightly associated with
cognitive stability (Cools, 2006), i.e., the
ability to maintain task-relevant repre-
sentations in the face of distractors or
interference (Miyake et al., 2000). Given
that the COMT gene modulates prefrontal
DA level, its polymorphism could pre-
dict improvement especially on tasks that
require cognitive stability.
Another candidate for modulating the
effect of TYR supplementation is the
C957T polymorphism in the DRD2 gene,
which is linked to messenger RNA sta-
bility (Duan et al., 2003), leading to
variation in extrastriatal D2 receptor avail-
ability (Hirvonen et al., 2009a) and stri-
atal DA level (Hirvonen et al., 2009b).
Specifically, T-carriers have reduced mes-
senger RNA stability, which results in
less striatal DA than homozygotic C-
carriers. Correspondingly, T-carriers show
less inhibitory control (Colzato et al., 2010,
2013b) and worse memory performance
(Li et al., 2013). Also related to striatal
DA is a second gene called DAT1, which
is involved in DA reuptake (Lewis et al.,
2001). Although there have been con-
tradictory findings on how the varying
number of base pair repeats in this gene
relates to DA transporter (DAT) availabil-
ity, recent studies suggest that 10-repeat
homozygotes have lesser DAT availability,
and consequently more striatal DA, than
9-repeat carriers (van de Giessen et al.,
2009; Shumay et al., 2011). This is con-
sistent with the finding that 10-repeat
carriers are better than 9-repeat carriers
at updating stimulus-response bindings
(Colzato et al., 2013c), which is thought to
be driven by DA (Colzato et al., 2007a,b).
Given that both T-carriers of the DRD2
gene and 9-repeat carriers of the DAT1
gene are likely to have less striatal DA,
we argue that especially they can bene-
fit from TYR supplementation, again per-
haps more so on tasks that require flexible
cognition.
Interestingly, the aforementioned
effect of the DRD2 polymorphism on
inhibitory control and memory perfor-
mance is stronger in older individuals
than in younger ones (Colzato et al.,
2013b; Li et al., 2013). This is consistent
with the resource-modulation hypothesis
(Lindenberger et al., 2008), which states
that aging-related changes in neurophysi-
ology enlarge the effect of polymorphisms
on cognition. Given that DA systems
deteriorate with old age (Volkow et al.,
1998; Bäckman et al., 2000, 2006; Erixon-
Lindroth et al., 2005), it is important
to take characteristics such as age into
consideration when investigating the
modulating effect of TYR on DA and
cognitive functions.
Last but not least is the tyrosine-
hydroxylase (TH) gene, which codes
for the enzyme that converts TYR into
L-DOPA (Daubner et al., 2011). The C-
824T-polymorphism in the TH gene has
been shown to influence urinary excretion
of norepinephrine, with carriers of the
T allele excreting more norepinephrine
(Rao et al., 2007). Horiguchi et al. (2014)
found that in patients with schizophrenia
the T allele is associated with increased
TH transcription activity and higher IQ.
These authors proposed that the resulting
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increase in norepinephrine levels in the
brain may have protected the patients
from cognitive decline. Higher levels of
norepinephrine suggest higher levels of
DA as well, since DA is the precursor of
norepinephrine (Buu and Kuchel, 1979).
Therefore, these findings have two inter-
esting implications for studies on TYR.
First, the higher TH transcription activity
associated with the T allele in the C-824T
polymorphism could mean that low base-
line DA individuals who carry this allele
can benefit especially from TYR supple-
mentation, as more TYR can be converted
into DA. Second, the idea that the T
allele protects against cognitive decline
in schizophrenia could imply that it does
so in old age as well. In that case, the
effect of this polymorphism on TYR sup-
plementation might be strongest in older
individuals, as might be the case with the
DRD2 gene. This possibility again under-
scores the need to keep age and age-related
changes in neurophysiology in mind when
investigating TYR.
CONCLUSION
The amino-acid TYR is a promising
cognitive enhancer, yet studies on how
TYR supplementation can benefit cogni-
tive performance are still scarce. We sug-
gest that future studies on TYR should
take into account individual differences
related to DA function, and to that end we
have listed several indicators and modula-
tors of DA that could predict the effect of
TYR supplementation. It should be noted
that these factors are unlikely to operate
independently from each other. For exam-
ple, individuals carrying the Val allele of
the COMT polymorphism, which indi-
cates a low prefrontal DA level, could
benefit especially from TYR when also car-
rying the T allele of the TH gene, since
that would allow more conversion of TYR
into DA. As such, interactions between
the presently suggested modulators should
be taken into account, to achieve a better
understanding of their implications for the
effect of TYR supplementation.
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